Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy

International Journal of Clinical Oncology

Volumn 21, Issue 1, 2016, Pages 118-125

  Kou, Tadayuki ^a   Kanai, Masashi ^b   Yamamoto, Michio ^b   Xue, Peng ^b   Mori, Yukiko ^b   Kudo, Yasushi ^a   Kurita, Akira ^a   Uza, Norimitsu ^b   Kodama, Yuzo ^b   Asada, Masanori ^a   Kawaguchi, Michiya ^b   Masui, Toshihiko ^b   Mizumoto, Masaki ^b   Yazumi, Shujiro ^a   Matsumoto, Shigemi ^b   Takaori, Kyoichi ^b   Morita, Satoshi ^b   Muto, Manabu ^b   Uemoto, Shinji ^b   Chiba, Tsutomu ^b  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Palliative chemotherapy; Pancreatic cancer; Prognostic model

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ERLOTINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; BLOOD; HEALTH STATUS; LYMPHOCYTE; LYMPHOCYTE COUNT; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PALLIATIVE THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; THEORETICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HEALTH STATUS; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEUTROPHILS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE;

EID: 84957933673     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0864-x     Document Type: Article

References (39)

1. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617
2. Ueno H, Okada S, Okusaka T et al (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4):296–301
3. Morizane C, Okusaka T, Morita S et al (2011) Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 40(3):415–421
4. Humphris JL, Chang DK, Johns AL et al (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 23(7):1713–1722
5. Bauer TM, El-Rayes BF, Li X et al (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 119(2):285–292
6. Stotz M, Gerger A, Eisner F et al (2013) Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 109(2):416–421
7. Hamada T, Nakai Y, Yasunaga H et al (2014) Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer 110(8):1943–1949
8. Szkandera J, Stotz M, Absenger G et al (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110(1):183–188
9. Xue P, Kanai M, Mori Y et al (2014) Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 3(2):406–415
10. Xue P, Kanai M, Mori Y et al (2014) Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Pancreas 43(3):411–416
11. Proctor MJ, McMillan DC, Morrison DS et al (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699
12. Cho IR, Park JC, Park CH et al (2014) Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 17(4):703–710
13. Li MX, Liu XM, Zhang XF et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134(10):2403–2413
14. McNamara MG, Templeton AJ, Maganti M et al (2014) Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 50(9):1581–1589
15. Pinato DJ, Shiner RJ, Seckl MJ et al (2014) Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer 110(8):1930–1935
16. Xiao WK, Chen D, Li SQ et al (2014) Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer 14:117
17. Teramukai S, Ochiai K, Tada H et al (2007) PIEPOC: a new prognostic index for advanced epithelial ovarian cancer–Japan Multinational Trial Organization OC01-01. J Clin Oncol 25(22):3302–3306
18. Park MJ, Lee J, Hong JY et al (2009) Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 115(7):1518–1530
19. Kanagavel D, Pokataev IA, Fedyanin MY et al (2010) A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 21(9):1779–1785
20. Halabi S, Lin CY, Kelly WK et al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32(7):671–677
21. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413
22. Ueno H, Okusaka T, Ikeda M et al (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68(2–3):171–178
23. Nakamura K, Yamaguchi T, Ishihara T et al (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94(11):1575–1579
24. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 25(15):1960–1966
25. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
26. Tanaka T, Ikeda M, Okusaka T et al (2008) Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38(11):755–761
27. Papadoniou N, Kosmas C, Gennatas K et al (2008) Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 28(1B):543–549
28. Haas M, Laubender RP, Stieber P et al (2010) Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 31(4):351–357
29. Steyerberg EW (2009) Clinical Prediction Models. Springer, New York
30. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387
31. Harrell FE, Califf RM, Pryor DB et al (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546
32. Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61(4):615–621
33. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825
34. Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31(13):1640–1648
35. Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703
36. Luo G, Guo M, Liu Z et al (2015) Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol 22(2):670–676
37. Inoue D, Ozaka M, Matsuyama M et al (2015) Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol 45(1):61–66
38. Qi Q, Geng Y, Sun M, et al (2015) Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology. [Epub ahead of print]
39. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39(1):2–15